Advanced Therapy for Hepatitis C

  • ID: 2096059
  • December 2011
  • 232 Pages
  • John Wiley and Sons Ltd
1 of 4

Hepatologists, both researchers and front-line clinicians, now have a comprehensive guide to the treatment of patients with the HCV virus. This book focuses mainly on the efficacy and clinical use of antiviral therapies, including the use of antivirals post liver transplantation and in the presence of the HIV virus. It also explores the foundations for understanding antiviral therapies in HCV, such as the complex pharmacology and mechanisms of antiviral drugs. A 'late-breaking information' chapter contains the most recent trial results on the latest antiviral drugs.

Note: Product cover images may vary from those shown
2 of 4

Contributors, vii

Preface, xi

Section I Foundations for Understanding Antiviral Therapies in HCV

1 HCV Replication, 3
Michael R. Beard

2 Hepatitis C Virus Genotypes, 12
Scott A. Read and Mark W. Douglas

3 Immune Responses to HCV: Implications for Therapy, 17
David G. Bowen

4 Mechanisms of Action of Antiviral Drugs: The Interferons, 25
Edmund Tse and Michael R. Beard

5 Pharmacology and Mechanisms of Action of Antiviral Drugs: Ribavirin Analogs, 36
Fred Poordad and Grace M. Chee

6 Pharmacology and Mechanisms of Action of Antiviral Drugs: Polymerase Inhibitors, 43
Lotte Coelmont, Leen Delang, Mathy Froeyen, Piet Herdewijn and Johan Neyts

7 Pharmacology and Mechanisms of Action of Antiviral Drugs: Protease Inhibitors, 53
Laurent Chatel-Chaix, Martin Baril and Daniel Lamarre

8 Measuring Antiviral Responses, 60
Jean-Michel Pawlotsky and Stephane Chevaliez

Section II Efficacy and Clinical Use of Antiviral Therapies

9 Genotype 1: Standard Treatment, 67
Rebekah G. Gross and Ira M. Jacobson

10 Individually Tailored Treatment Strategies in Treatment-na¨ive Chronic Hepatitis C Genotype 1 Patients, 74
Johannes Wiegand and Thomas Berg

11 Genotype 1 Relapsers and Non-responders, 84
Salvatore Petta and Antonio Crax`i

12 Standard Therapy for Genotypes 2/3, 90
Kenneth Yan and Amany Zekry

13 Altered Dosage or Durations of Current Antiviral Therapy for HCV Genotypes 2 and 3, 97
Alessandra Mangia, Leonardo Mottola and Angelo Andriulli

14 Genotypes 2 and 3 Relapse and Non-response, 104
Stella Mart´inez, Jose Maria Sanchez-Tapias and Xavier Forns

15 Hepatitis C Genotype 4 Therapy: Progress and Challenges, 113
Sanaa M. Kamal

16 Antivirals in Acute Hepatitis C, 127
Heiner Wedemeyer

17 Antivirals in Cirrhosis and Portal Hypertension, 132
Diarmuid S. Manning and Nezam H. Afdhal

18 Treatment of Recurrent Hepatitis C Following Liver Transplantation, 140
Ed Gane

19 Antiviral Treatment in Chronic Hepatitis C Virus Infection with Extrahepatic Manifestations, 150
Benjamin Terrier and Patrice Cacoub

20 Cytopenias: How they Limit Therapy and Potential Correction, 160
Mitchell L. Shiffman

21 The Problem of Insulin Resistance and its Effect on Therapy, 169
Venessa Pattullo and Jacob George

22 HIV and Hepatitis C Co-infection, 177
Gail V. Matthews and Gregory J. Dore

23 HCV and Racial Differences, 185
Andrew J. Muir

24 HCV and the Pediatric Population, 190
Kathleen B. Schwarz

25 New Horizons: IL28, Direct-acting Antiviral Therapy for HCV, 196
Alexander J. Thompson, John G. McHutchison and Geoffrey W. McCaughan


Note: Product cover images may vary from those shown
3 of 4

“I think it is an invaluable respository of knowledge for anyone embarking on a career caring for patients with viral hepatitis. This book summarises the hard won clinical knowledge of the past 20 years.”  (The Irish Medical Journal, 1 January 2013)

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown


  • Quick Help: The book will be shipped to you. The cover has a hard back.


If you have a more general question about our products please try our



Our Clients

  • AB Sciex
  • Eli Lilly and Company
  • B. Braun Melsungen AG
  • Astellas Pharma, Inc.
  • Hologic Inc.
  • Merck & Co., Inc.